Benda Pharmaceutical, Inc. Appoints Eric Yu Tak Shing as Its Chief Financial Officer Monday February 12, 9:25 am ET
HUBEI PROVINCE, CHINA--(MARKET WIRE)--Feb 12, 2007 -- Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTC BB:BPMA.OB - News), a Chinese-based pharmaceutical company engaged in the development, manufacturing and distribution of medicines, active pharmaceutical ingredients and pharmaceutical intermediaries, announced today the appointment of Eric Yu Tak Shing as Chief Financial Officer effective February 9, 2007. Mr. Yu is a certified public account (CPA, Hong Kong and CPA, Australia) with 13 years of experience in public and corporate accounting and finance, most recently as Financial Controller of Beijing Teletron Telecom Engineering Co., Ltd. Mr. Yu began his career in 1993 with BDO Kwan Wong Tan & Fong, which was acquired by Deloitte Touche Tohmatus in 1996. He has held progressively more responsible positions with companies in China, Hong Kong, Australia and the United States, gaining in-depth knowledge and understanding of the accounting procedures, standards and issues in accordance with PRC GAAP, US GAAP and Hong Kong GAAP. Mr. Yu is fluent in English, Mandarin and Cantonese. He holds a Bachelor of Commerce Degree in Accountancy and Legal Studies from the University of Wollongong in Australia.
"Benda Pharmaceutical is deeply committed to fulfilling its corporate responsibilities as a U.S. public company," said Benda CEO, Yiqing Wan. "The appointment of Mr. Yu as Benda's Chief Financial Officer is an important milestone and one essential to that effort. His intimate knowledge of U.S. GAAP and the U.S. capital markets will help us develop the rigorous discipline in our corporate governance, financial reporting and investor communications that will be required on our path to eventually becoming a NASDAQ listed stock."
Posts: 298 | Registered: May 2006
| IP: Logged |